Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFFWD.L Regulatory News (FFWD)

  • There is currently no data for FFWD

Trading Update

6 Sep 2006 07:30

London Asia Chinese Private Equity06 September 2006 6 September 2006 London Asia Chinese Private Equity Fund Limited ("LACPEF" or "the Fund") Investee Companies Trading On PLUS LACPEF, the China focused investment fund, is pleased to announce that two moreof its investee companies are to begin trading on the UK's PLUS Markets StockMarket. China New Energy Ltd ("CNE") is expected to begin trading today at 525p a share,giving it a market capitalisation of £35 million. Its core business is thesupply of turnkey technology solutions for the production of ethanol, ediblealcohol and acetic acid from a range of bio-resources, including corn,sugarcane, cassava and other bio-resources. As part of the listing process, theFund has invested a further £0.35 million, bringing its total investment in CNEto date to £2.2 million for a 25% stake. CNE is seeking a listing to enable itto tap into the international market for its product, with sales currentlyfocused on the Chinese market. China Biofoods Ltd ("Biofoods") is expected to begin trading on Thursday 7September at 175p a share, giving it a market capitalisation of £12.5 million.The Fund took a 31% stake in June at a cost of £2.1 million. Biofoodsspecialises in the production of highly purified herb extract products, whichare then used to produce traditional Chinese medicine, and as ingredients infunctional foods. China Biofoods reported revenues of £2.9m with profit aftertax of £1.2m for the year ended 31 December 2005. It is listing on PLUS as away of tapping into the international market for its products. Simon Littlewood, Executive Director of LACPEF, commented: "These listings onPLUS follow the successful listing of our investee company Dalian BusinessInstitute in May, with Dalian currently trading at a market capitalisation ofover £18 million, valuing the Fund's stake at £3.6 million against an investmentcost of £2.0 million. The listings demonstrate the value in our investmentportfolio. CNE is listing as it will need considerable amounts of capital goingforward as it seeks to take advantage of its leading position in the ethanolsector in China, where as a result of recent changes in legislation there hasbeen a rapid expansion in the size of the market, as well as taking advantage ofopportunities outside China, with ethanol being looked at worldwide as apotential alternative to highly priced oil. Biofoods is expanding its productrange, and looking to tie up with international partners to sell its productsoverseas." For further information please visit www.londonasiafunds.com or contact: John West/Matt Ridsdale Simon Littlewood Hugh FieldTavistock Communications London Asia Capital plc Collins Stewart LimitedTel: 020 7920 3150 Tel 020 7355 7928 Tel: 020 7523 8000 About China New Energy CNE has established itself as the leading brand in China, with an estimated 60%share of the market for ethanol production equipment in China. The Company'ssuccessful track record is key to growing the business and its technology hasbeen used in over 30 projects. CNE is supported by strong drivers with thedemand for ethanol, a fuel seen as an alternative to oil, growing rapidly andsupported by a recent change in legislation in China requiring 10% of allvehicle oil consumption to be biofuel in 11 of China's Provinces. Similarlegislation is coming into force in many countries, such as the US and EU,creating a potential market for CNE to export its products going forward. For additional information, visit the Company's web site atwww.chinanewenergygroup.com About China Biofoods Biofoods is based in Xuchang, Henan Province, the centre for farming traditionalChinese medical herbs. It specialises in the production of highly purified herbextract products, which are then used to produce traditional Chinese medicine,and as ingredients in functional foods. The market for "Functional Foods" is expanding rapidly worldwide, especially inChina. "Functional Foods" are foods or dietary components that may provide ahealth benefit beyond their basic nutritional value. Such products are aimed ata wide variety of markets, from those with poor diets and limited resourcesseeking additional nutritional content in their diet, to those whose lifestylesand levels of stress require them to eat more healthy food, to the aged who areseeking traditional cures to age related ailments. Biofoods' core products are highly purified linolenic acids, Reshi mushroomspore oil, and deodorized garlic oil. Linolenic acid, also known as Vitamin F,is an essential fatty acid which is not produced by the body, and has been usedto improve hair and skin, reduce blood pressure, help prevent arthritis, lowercholesterol and triglycerides, and reduce the risk of blood clots. Reshimushroom spore oil is broadly used in the health food industry as a supplementand intermediate ingredient. For additional information, please visit the company's web pagewww.chinabiofoods.com.cn This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
18th Feb 20207:00 amRNSInvestee Company Update: EMMAC Life Sciences
11th Feb 20207:00 amRNSUpdated Key Information Document
31st Jan 20201:30 pmRNSInvestee Company Update: Portage Biotech Inc.
8th Jan 20207:00 amRNSDisposal of Interest in Cryptologic Corp
7th Jan 20207:00 amRNSBoard Appointment
3rd Jan 20201:15 pmRNSInvestee Company Update: Portage Biotech Inc.
11th Dec 20197:00 amRNSHalf-year Report
5th Dec 20192:45 pmRNSTR-1 Notification
19th Nov 20197:00 amRNSLorne Abony appointed as Chairman of EMMAC
16th Oct 20197:00 amRNSInvestee Company Update: EMMAC Life Sciences
15th Oct 20197:00 amRNSInvestee Company Update: Factom inc.
10th Oct 20199:25 amRNSResult of 2019 AGM
27th Sep 20194:31 pmRNSDirector Dealing in the Company
27th Sep 20197:00 amRNSInvestee Company Update : Fralis LLC (Leap Gaming)
26th Sep 201911:21 amRNSInvestee Company Update : Cryptologic Corp
16th Sep 201911:52 amRNSTR-1 Notification of major holdings
11th Sep 20198:00 amRNSResults for the year ended 31st March 2019
11th Sep 20198:00 amRNSNotice of 2019 Annual General Meeting
22nd Aug 201912:01 pmRNSDirectorate Change
19th Aug 20199:23 amRNSJuvenescence closes Series B funding
12th Aug 20193:02 pmRNSInvestee Company Update-Cryptologic issues loan
12th Aug 201910:11 amRNSPortage Trading Suspended
6th Aug 20194:42 pmRNSInvestee Company Update: Cryptologic Corp
30th Jul 201911:07 amRNSSAFE Agreement with Factom, Inc. Extended
25th Jul 20198:17 amRNSFactom Inc SAFE Agreement temporary extension
18th Jul 201911:20 amRNSInvestee Company Update: Regent Pacific on Yooya
16th Jul 20199:13 amRNSInvestee Company Update:EMMAC acquires Terre Verde
11th Jul 20193:00 pmRNSDisposal of interest in Intensity Therapeutics Inc
9th Jul 201910:51 amRNSInvestee Company Update: EMMAC enters new Market
26th Jun 20198:56 amRNSInvestee Company Update: Intensity Therapeutics
29th May 20193:43 pmRNSInvestee Company Update: Offer for Yooya
13th May 201910:21 amRNSDisposal of interest in Vemo Education Inc.
18th Apr 20197:00 amRNSInvestee Company Update: Intensity Therapeutics
4th Apr 20199:51 amRNSTR1 - Correction
3rd Apr 20194:00 pmRNSTR:1 Regent Mercantile Holdings Limited
20th Mar 201911:00 amRNSCompletion of £2 million investment in EMMAC
7th Mar 20194:03 pmRNS£2 million investment in EMMAC Life Sciences
15th Jan 20193:45 pmRNSJuvenescence Series B Funding
3rd Jan 201911:47 amRNSBoard Appointment
12th Dec 201812:52 pmRNSHalf-year Report
3rd Dec 20187:00 amRNSInvestee Company Update: Factom and Yooya
14th Nov 20181:31 pmRNSInvestee Company Update: Factom Inc
22nd Oct 201812:24 pmRNSIntensity Therapeutics Inc Update
12th Sep 20186:12 pmRNSResult of AGM
10th Sep 20189:16 amRNSHolding(s) in Company
22nd Aug 20188:08 amRNSDirector Dealing
3rd Aug 201812:48 pmRNSShareholder update
3rd Aug 20188:00 amRNSPlacing
1st Aug 201812:05 pmRNSResponse to Media Speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.